

Amendments to the Specification

Please amend the Specification (as-published) as follows:

(1) Please amend paragraph [0013] of the Specification as-published as follows:

[0013] 12) a coated preparation obtained according to the production method of the aforementioned 1), which shows elution of not less than 50% of pioglitazone hydrochloride in 15 minutes in a dissolution test by a ~~puddle~~ paddle method using a hydrochloric acid-potassium chloride buffer (pH 2.0) as a test solution at 37° C, 50 rpm; and the like.

(2) Please amend paragraph [0080] of the Specification as-published as follows:

[0080] The present invention moreover relates to "a coated preparation obtained according to the production method of the present invention, which shows elution of not less than 50% of pioglitazone hydrochloride in 15 minutes in a dissolution test by a ~~puddle~~ paddle method using a hydrochloric acid-potassium chloride buffer (pH 2.0) as a test solution at 37° C, 50 rpm". As used herein, the dissolution test is performed according to the method described in The Japanese Pharmacopoeia 14th Edition. The "hydrochloric acid-potassium chloride buffer (pH 2.0)" used as a test solution can be prepared according to a known method. The amount of the hydrochloric acid-potassium chloride buffer used as a test solution is generally 900 mL.

(3) Please amend paragraph [0081] of the Specification as-published as follows:

[0081] The "coated preparation obtained according to the production method of the present invention, which shows elution of not less than 50% of pioglitazone hydrochloride in 15 minutes in a dissolution test by a ~~puddle~~ paddle method using a hydrochloric acid-potassium chloride buffer (pH 2.0) as a test solution at 37° C, 50 rpm" can be administered orally and safely to mammals (e.g., mouse, rat, rabbit, cat, dog, bovine, horse, monkey, human and the like), as the aforementioned coated preparation of the present invention, wherein the target disease, dose and the like are the same as those in the aforementioned coated preparation of the present invention.

(4) Please amend paragraph [0093] of the Specification as-published as follows:

[0093] The coated preparations obtained in the aforementioned Example 2 and Example 3 were evaluated for the dissolution property of pioglitazone hydrochloride by a ~~puddle~~ paddle method (50 rpm) using a 0.3 M hydrochloric acid-potassium chloride buffer (900 mL, 37° C, pH 2.0). The results are shown in Table 2.